Gilead Sciences (NASDAQ:GILD) Stock Price Expected to Rise, BMO Capital Markets Analyst Says

Key Points

• BMO Capital Markets has raised its price target for Gilead Sciences from $130 to $135, indicating a potential upside of 10.11% from the current stock price.
• Needham & Company upgraded Gilead's rating from "hold" to "buy," setting a target price of $133, while the company holds a consensus rating of "Moderate Buy."
• Insider trading activity shows CEO Daniel O'Day recently sold 10,000 shares, indicating a 1.65% decrease in ownership, while overall, institutional investors own 83.67% of Gilead Sciences stock.

Gilead Sciences (NASDAQ:GILD - Get Free Report) had its price objective increased by stock analysts at BMO Capital Markets from $130.00 to $135.00 in a research report issued to clients and investors on Monday,MarketScreener reports. The brokerage presently has an "outperform" rating on the biopharmaceutical company's stock. BMO Capital Markets' price target points to a potential upside of 10.11% from the stock's current price.

GILD has been the topic of a number of other research reports. Needham & Company LLC upgraded Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 target price on the stock in a report on Friday, July 25th. The Goldman Sachs Group upped their price objective on shares of Gilead Sciences from $105.00 to $108.00 and gave the company a "neutral" rating in a research note on Friday. Daiwa America raised shares of Gilead Sciences from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, August 19th. Cantor Fitzgerald raised their price objective on Gilead Sciences from $129.00 to $135.00 and gave the stock an "overweight" rating in a report on Thursday, October 9th. Finally, Royal Bank Of Canada raised their price target on Gilead Sciences from $98.00 to $100.00 and gave the stock a "sector perform" rating in a research note on Wednesday, October 8th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and six have assigned a Hold rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $120.04.

Gilead Sciences Trading Down 0.2%

Shares of GILD opened at $122.61 on Monday. The firm's 50-day moving average is $115.22 and its two-hundred day moving average is $110.51. Gilead Sciences has a twelve month low of $85.60 and a twelve month high of $124.11. The company has a current ratio of 1.32, a quick ratio of 1.15 and a debt-to-equity ratio of 1.13. The firm has a market capitalization of $152.13 billion, a P/E ratio of 24.42, a PEG ratio of 0.84 and a beta of 0.34.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.96 by $0.05. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The firm had revenue of $7.08 billion during the quarter, compared to analysts' expectations of $6.95 billion. During the same period in the previous year, the firm posted $2.01 earnings per share. Gilead Sciences's revenue was up 1.4% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. On average, research analysts predict that Gilead Sciences will post 7.95 earnings per share for the current fiscal year.

Insider Activity

In other news, CEO Daniel Patrick O'day sold 10,000 shares of the stock in a transaction dated Thursday, August 28th. The shares were sold at an average price of $113.63, for a total transaction of $1,136,300.00. Following the transaction, the chief executive officer owned 595,725 shares of the company's stock, valued at approximately $67,692,231.75. This trade represents a 1.65% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Andrew D. Dickinson sold 2,500 shares of the company's stock in a transaction that occurred on Wednesday, October 15th. The shares were sold at an average price of $118.08, for a total value of $295,200.00. Following the sale, the chief financial officer owned 157,055 shares in the company, valued at $18,545,054.40. The trade was a 1.57% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 71,500 shares of company stock worth $8,281,540. 0.27% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Gilead Sciences

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Rothschild Investment LLC boosted its holdings in shares of Gilead Sciences by 1.9% during the 2nd quarter. Rothschild Investment LLC now owns 4,539 shares of the biopharmaceutical company's stock worth $503,000 after buying an additional 84 shares during the period. Ignite Planners LLC increased its stake in shares of Gilead Sciences by 1.1% in the third quarter. Ignite Planners LLC now owns 7,932 shares of the biopharmaceutical company's stock worth $880,000 after purchasing an additional 86 shares during the period. Archer Investment Corp boosted its stake in Gilead Sciences by 1.2% during the 2nd quarter. Archer Investment Corp now owns 7,277 shares of the biopharmaceutical company's stock valued at $807,000 after purchasing an additional 87 shares during the period. Binnacle Investments Inc raised its stake in Gilead Sciences by 14.3% during the 2nd quarter. Binnacle Investments Inc now owns 702 shares of the biopharmaceutical company's stock valued at $78,000 after purchasing an additional 88 shares during the last quarter. Finally, EPG Wealth Management LLC boosted its holdings in Gilead Sciences by 2.0% in the 2nd quarter. EPG Wealth Management LLC now owns 4,627 shares of the biopharmaceutical company's stock valued at $513,000 after purchasing an additional 89 shares during the period. Institutional investors own 83.67% of the company's stock.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.